Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings

被引：83

作者：

Hummel, Horst-Dieter ^{[1
]}

Kufer, Peter ^{[2
]}

Gruellich, Carsten ^{[3
,4
]}

Seggewiss-Bernhardt, Ruth ^{[1
,5
]}

Deschler-Baier, Barbara ^{[6
]}

Chatterjee, Manik ^{[1
]}

Goebeler, Maria-Elisabeth ^{[7
]}

Miller, Kurt ^{[8
]}

de Santis, Maria ^{[8
,9
]}

Loidl, Wolfgang ^{[10
]}

Dittrich, Christian ^{[11
,12
]}

Buck, Andreas ^{[13
]}

Lapa, Constantin ^{[13
,14
]}

Thurner, Annette ^{[15
]}

Wittemer-Rump, Sabine ^{[16
]}

Koca, Gokben ^{[16
]}

Boix, Oliver ^{[16
]}

Doecke, Wolf-Dietrich ^{[16
]}

Finnern, Ricarda ^{[16
]}

Kusi, Helena ^{[16
]}

Ajavon-Hartmann, Antoinette ^{[16
]}

Stienen, Sabine ^{[2
]}

Sayehli, Cyrus Michael ^{[17
]}

Polat, Buelent ^{[18
]}

Bargou, Ralf C. ^{[6
]}

机构：

[1] Univ Hosp Wurzburg, Comprehens Canc Ctr Mainfranken, Translat Oncol Early Clin Trial Unit ECTU, Oberdurrbacherstr 6, D-97080 Wurzburg, Germany

[2] Amgen Res Munich GmbH, Res & Dev, Staffelseestr 2, D-81477 Munich, Germany

[3] Heidelberg Univ, Med Ctr, Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany

[4] Univ Hosp Dresden, Dept Hematol & Oncol, Haus 27,Fetscherstr 74, D-01307 Dresden, Germany

[5] Sozialstiftung Bamberg, Med Klin 5, Buger Str 80, D-96049 Bamberg, Germany

[6] Univ Hosp Wurzburg, Comprehens Canc Ctr Mainfranken, Translat Oncol, Josef Schneider Str 6, D-97080 Wurzburg, Germany

[7] Univ Hosp Wurzburg, Med Klin 2, Translat Oncol Early Clin Trial Unit ECTU, Oberdurrbacherstr. 6, D-97080 Wurzburg, Germany

[8] Charite Univ Med Berlin, Dept Urol, Charitepl 1, D-10117 Berlin, Germany

[9] Med Univ Vienna, Dept Urol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria

[10] Ordensklinikum Linz GmbH Elisabethinen, Dept Urol, Fadingerstr 1, A-4020 Linz, Austria

[11] Kaiser Franz Josef Spital, Inst Translat Res Vienna ACRI TR VIEnna, Appl Canc Res, Bernardgasse 24-2, A-1070 Vienna, Austria

[12] Kaiser Franz Josef Spital, Ctr Oncol & Hematol, Bernardgasse 24-2, A-1070 Vienna, Austria

[13] Univ Hosp Wurzburg, Dept Nucl Med, Oberdurrbacherstr 6, D-97080 Wurzburg, Germany

[14] Univ Augsburg, Med Fac, Nucl Med, Stenglinstr 2, D-86156 Augsburg, Germany

[15] Univ Hosp Wurzburg, Dept Diagnost & Intervent Radiol, Oberdurrbacherstr 6, D-97080 Wurzburg, Germany

[16] Bayer AG, SBU Oncol, Pharmaceut, D-13353 Berlin, Germany

[17] Univ Hosp Wurzburg, Med Klin 2, Translat Oncol Early Clin Trial Unit ECTU, Oberdurrbacherstr 6, D-97080 Wurzburg, Germany

[18] Univ Hosp Wurzburg, Dept Radiat Oncol, Josef Schneider Str 11, D-97080 Wurzburg, Germany

来源：

IMMUNOTHERAPY | 2021年 / 13卷 / 02期

关键词：

AMG; 212; BAY; 2010112; bispecific T-cell engager (BiTE (R)) immune therapy; pasotuxizumab; PSMA; prostate cancer; MEMBRANE ANTIGEN; T-CELLS; NIVOLUMAB; CHEMOTHERAPY; ANTIBODY; PEMBROLIZUMAB; IPILIMUMAB; REGRESSION; CARCINOMA;

D O I：

10.2217/imt-2020-0256

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Aim: We report results of a first-in-human study of pasotuxizumab, a PSMA bispecific T-cell engager (BiTE (R)) immune therapy mediating T-cell killing of tumor cells in patients with advanced castration-resistant prostate cancer. Patients & methods: We assessed once-daily subcutaneous (SC) pasotuxizumab. All SC patients developed antidrug antibodies; therefore, continuous intravenous (cIV) infusion was assessed. Results: A total of 47 patients received pasotuxizumab (SC: n = 31, 0.5-172 mu g/d; cIV: n = 16, 5-80 mu g/d). The SC maximum tolerated dose was 172.0 mu g/d. A sponsor change stopped the cIV cohort early; maximum tolerated dose was not determined. PSA responders occurred (>50% PSA decline: SC, n = 9; cIV, n = 3), including two long-term responders. Conclusion: Data support pasotuxizumab safety in advanced castration-resistant prostate cancer and represent evidence of BiTE monotherapy efficacy in solid tumors. Clinical trial registration:NCT01723475 (ClinicalTrials.gov)

引用

页码：125 / 141

页数：18

共 50 条

[21] Phase I dose-escalation study of AGS-1C4D4, an anti-PSCA human antibody in castration-resistant prostate cancer (CRPC)
Carducci, M. A.
Eisenberger, M. A.
Denmeade, S. R.
Slovin, S. F.
Jakobovits, A.
Vincent, M.
Scher, H. I.
Morris, M. J.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[22] Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).
Tagawa, Scott T.
Osborne, Joseph
Fernandez, Escarleth
Thomas, Charlene
Niaz, Muhammad Junaid
Ciriaco, Amy
Vallabhajosula, Shankar
Vlachostergios, Panagiotis J.
Molina, Ana M.
Sternberg, Cora N.
Singh, Sharon
Babich, John
Nanus, David M.
Ballman, Karla, V
Bander, Neil Harrison
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[23] Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC)
Tagawa, Scott T.
Osborne, Joseph
Niaz, Muhammad Junaid
Vallabhajosula, Shankar
Vlachostergios, Panagiotis J.
Thomas, Charlene
Molina, Ana M.
Sternberg, Cora N.
Singh, Sharon
Fernandez, Escarleth
Babich, John
Nanus, David M.
Ballman, Karla V.
Bander, Neil Harrison
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[24] Phase I dose-escalation study of fractionated-dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).
Tagawa, Scott T.
Vallabhajosula, Shankar
Batra, Jaspreet
Christos, Paulj.
Jhanwar, Yuliya
Goldsmith, Stanley J.
Nanus, David M.
Beltran, Himisha
Molina, Ana M.
Faltas, Bishoy
Hackett, Amy
Sreekumar, Jyothi
Babich, John
Bander, Neil Harrison
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[25] A phase I dose-escalation study of LAE001/prednisone plus afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following standard of care (SOC) treatment
Bessudo, A.
Wang, X.
Strauss, J. F.
Slater, D. E.
Pieczonka, C.
Guo, P.
Liu, J.
Yue, Y.
Lu, C.
ANNALS OF ONCOLOGY, 2021, 32 : S644 - S645
[26] Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer
Masahiro Nozawa
Hirofumi Mukai
Shunji Takahashi
Hiroji Uemura
Takeo Kosaka
Yusuke Onozawa
Jun Miyazaki
Kazuhiro Suzuki
Koji Okihara
Yoichi Arai
Tomomi Kamba
Masashi Kato
Yasutomo Nakai
Hiroshi Furuse
Haruki Kume
Hisamitsu Ide
Hiroshi Kitamura
Akira Yokomizo
Takahiro Kimura
Yoshihiko Tomita
Keiji Ohno
Yoshiyuki Kakehi
International Journal of Clinical Oncology, 2015, 20 : 1026 - 1034
[27] A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer
Courtney, Kevin D.
Manola, Judith B.
Elfiky, Aymen A.
Ross, Robert
Oh, William K.
Yap, Jeffrey T.
Van den Abbeele, Annick D.
Ryan, Christopher W.
Beer, Tomasz M.
Loda, Massimo
Priolo, Carmen
Kantoff, Philip
Taplin, Mary-Ellen
CLINICAL GENITOURINARY CANCER, 2015, 13 (02) : 113 - 123
[28] Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer
Nozawa, Masahiro
Mukai, Hirofumi
Takahashi, Shunji
Uemura, Hiroji
Kosaka, Takeo
Onozawa, Yusuke
Miyazaki, Jun
Suzuki, Kazuhiro
Okihara, Koji
Arai, Yoichi
Kamba, Tomomi
Kato, Masashi
Nakai, Yasutomo
Furuse, Hiroshi
Kume, Haruki
Ide, Hisamitsu
Kitamura, Hiroshi
Yokomizo, Akira
Kimura, Takahiro
Tomita, Yoshihiko
Ohno, Keiji
Kakehi, Yoshiyuki
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (05) : 1026 - 1034
[29] Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC).
Hummel, Horst-Dieter
Kufer, Peter
Gruellich, Carsten
Deschler-Baier, Barbara
Chatterjee, Manik
Goebeler, Maria-Elisabeth
Miller, Kurt
De Santis, Maria
Loidl, Wolfgang C.
Buck, Andreas
Wittemer-Rump, Sabine
Koca, Goekben
Boix, Oliver
Doecke, Wolf-Dietrich
Stienen, Sabine
Sayehli, Cyrus
Bargou, Ralf C.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[30] PHASE I DOSE-ESCALATION TRIAL OF MULTIPLE AND FRACTIONATED-DOSE PSMA-TARGETED ALPHA RADIONUCLIDE (225AC-J591) FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sun, Michael
Nauseef, Jones
Fajardo, Andres Ricaurte
Davidson, Zachary
Thomas, Joseph
Ruder, Samuel
Stangl-Kremser, Judith
Castellanos, Sandra Huicochea
Molina, Ana
Sternberg, Cora
Patel, Amie
Yuan, Sarah
Fernandez, Escarleth
Fung, Edward
Avlonitis, Vasilios
O'Dwyer, Elisabeth
Nanus, David
Osborne, Joseph
Bander, Neil
Tagawa, Scott
JOURNAL OF UROLOGY, 2024, 211 (05): : E67 - E68

← 1 2 3 4 5 →